Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VDR | P11473 | 3/20 | 0.79 |
| ▸ | USP2 | O75604 | 1/20 | 0.79 |
| ▸ | CDC25A | P30304 | 4/20 | 0.77 |
| ▸ | POLA1 | P09884 | 1/20 | 0.76 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.66 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.66 |
| ▸ | INPP5D | Q92835 | 1/20 | 0.65 |
| ▸ | ST6GAL1 | P15907 | 1/20 | 0.61 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.60 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19232373 | 1.00 | VDR (0.79) | VDRUSP2CDC25APOLA1CYP2D6 | |
| SCHEMBL4739364 | 1.00 | VDR (0.79) | VDRUSP2CDC25APOLA1CYP2D6 | |
| SCHEMBL15372968 | 1.00 | VDR (0.79) | VDRUSP2CDC25APOLA1CYP2D6 | |
| SCHEMBL11371121 | 1.00 | VDR (0.79) | VDRUSP2CDC25APOLA1CYP2D6 | |
| SCHEMBL106015 | 1.00 | VDR (0.79) | VDRUSP2CDC25APOLA1CYP2D6 | |
| SCHEMBL24403430 | 1.00 | VDR (0.79) | VDRUSP2CDC25APOLA1CYP2D6 | |
| SCHEMBL10052613 | 1.00 | VDR (0.79) | VDRUSP2CDC25APOLA1CYP2D6 | |
| SCHEMBL13214256 | 1.00 | VDR (0.79) | VDRUSP2CDC25APOLA1CYP2D6 | |
| SCHEMBL12205280 | 1.00 | VDR (0.79) | VDRUSP2CDC25APOLA1CYP2D6 | |
| SCHEMBL15289783 | 1.00 | VDR (0.79) | VDRUSP2CDC25APOLA1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030157158-A1 | Enhanced liposomal thioretinaco ozonide compositions and liposomal carrier | MCCULLY KILMER S (US) | 2003-08-21 | — | — | US | claimed |
| WO-2003057192-A1 | ENHANCED LIPOSOMAL THIORETINACO OZONIDE COMPOSITIONS AND LIPOSOMAL CARRIER | MCCULLY KILMER S (US) | 2003-07-17 | — | — | WO | claimed |
| JP-2200608-A | — | — | None | — | — | JP | disclosed |
| WO-2023142890-A1 | SYNTHESIS METHOD FOR HIGH-PURITY CHOLESTEROL | 华东师范大学 | 2023-08-03 | — | — | WO | disclosed |
| WO-2023142888-A1 | METHOD FOR SYNTHESIZING HIGH-PURITY PLANT-DERIVED CHOLESTEROL | 华东师范大学 | 2023-08-03 | — | — | WO | disclosed |
| WO-2008131192-A2 | CRYSTALLINE CHOLESTROL AND PREVENTION OF ATHEROSCLEROSIS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2008-10-30 | — | — | WO | disclosed |
| WO-2008077247-A1 | COATINGS FOR IMPLANTABLE MEDICAL DEVICES COMPRISING CHOLESTEROL | MIV THERAPEUTICS INC. (CA) | 2008-07-03 | — | — | WO | disclosed |
| US-6696082-B2 | COMPLEX COMPRISING N-HOMOCYSTEINE THIOLACTONYL RETINAMIDE, COBALAMIN, OZONE, OXYGEN, AND ADENOSINE TRIPHOSPHATE; ANTICARCINGENIC, ANTITUMOR, AND VIRICIDAL AGENTS; ATHEROSCLEROSIS PREVENTION; AGING RESISTANCE | MCCULLY KILMER S (US) | 2004-02-24 | — | — | US | disclosed |
| US-20030157158-A1 | Enhanced liposomal thioretinaco ozonide compositions and liposomal carrier | MCCULLY KILMER S (US) | 2003-08-21 | — | — | US | disclosed |
| WO-2003057192-A1 | ENHANCED LIPOSOMAL THIORETINACO OZONIDE COMPOSITIONS AND LIPOSOMAL CARRIER | MCCULLY KILMER S (US) | 2003-07-17 | — | — | WO | disclosed |
| US-6274118-B1 | INJECTING PATIENT HAVING ENDOCRINE CANCER IN NON-PROSTATIC TISSUE WITH BIOLOGICAL BINDING UNITS WHICH BIND TO PROSTATE SPECIFIC ANTIGEN PRODUCED BY NON-PROSTATIC TISSUE | NORDION INTERNATIONAL INC. (CA) | 2001-08-14 | — | — | US | disclosed |
| WO-1995002424-A1 | LOCALIZATION AND THERAPY OF NON-PROSTATIC ENDOCRINE CANCER WITH AGENTS DIRECTED AGAINST PROSTATE SPECIFIC ANTIGEN | NORDION INTERNATIONAL INC. (CA) | 1995-01-26 | — | — | WO | disclosed |
| JP-H02200608-A | COSMETIC | POLA CHEM IND INC | 1990-08-08 | — | — | JP | disclosed |